Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00183924
Status:
COMPLETED
Last Update Posted:
2014-05-22
First Post:
2005-09-09
Brief Title:
Estramustine Docetaxel and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy
Sponsor:
University of Southern California
Organization:
University of Southern California
Study Overview
Official Title:
A Phase II Pilot Study of Estramustine Docetaxel and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is for patients with prostate cancer that is metastatic progressive and resistant to hormonal manipulation and mitoxantrone chemotherapyPatients have previously been treated with surgical removal of the testes or hormone therapy and subsequently with chemotherapy that included the drug mitoxantrone Novantrone Patients will have prostate cancer that has worsened despite these treatments
We hope to learn whether the combination chemotherapy decreases cancer symptoms and tests and to determine how frequently serious side effects occur with acceptable toxicity from the chemotherapy
We hope to learn whether the combination chemotherapy decreases cancer symptoms and tests and to determine how frequently serious side effects occur with acceptable toxicity from the chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None